USPTO Patent Grant: Pharmaceutical Composition for Skin Disease
Summary
The USPTO has granted a patent (US12582680B2) to RIKEN for a pharmaceutical composition derived from ampicillin-sensitive bacteria to treat skin diseases. The patent covers bacterial cells, culture supernatants, extracts, and metabolites as active components.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582680B2 to RIKEN for a pharmaceutical composition aimed at preventing, ameliorating, or treating skin diseases. The invention utilizes components derived from ampicillin-sensitive bacteria, including bacterial cells, culture supernatants, extracts, or metabolites, identified through research on Tmem79-knockout model mice.
This patent grant is primarily an intellectual property protection for RIKEN's research and development. For pharmaceutical companies and drug manufacturers, this represents a new piece of intellectual property in the dermatology and biotechnology space. While not imposing direct regulatory obligations, it may influence future research, development, and commercialization strategies in the treatment of skin diseases, potentially requiring licensing or collaboration for related product development.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pharmaceutical composition for prevention, amelioration, or treatment of skin disease
Grant US12582680B2 Kind: B2 Mar 24, 2026
Assignee
RIKEN
Inventors
Yoshihiro Ito, Kenya Honda, Masayuki Amagai, Eiryo Kawakami
Abstract
In the present invention, the influence by flora of the skin on dermatitis is examined by analyzing Tmem79-knockout model mice, and a bacterium having a suppressive effect on dermatitis is identified, and the present invention relates to a pharmaceutical composition derived from such a bacterium, containing as active components one or more substances selected from: (a) a bacterial cell of an ampicillin-sensitive bacterium, or a constituent component of the bacterium; (b) a culture supernatant of an ampicillin-sensitive bacterium, or a purified product from the culture supernatant; (c) an extract of an ampicillin-sensitive bacterium; and (d) a metabolite of an ampicillin-sensitive bacterium.
CPC Classifications
A23L 33/135 A23L 33/17 A23L 33/185 A61K 35/747 A61K 35/74 A61P 1/00 A61P 17/00 A61P 17/04 A61P 17/06 C12N 1/205 C12N 1/20 A01K 2217/075 C12R 2001/44 G01N 2800/202 C12Q 1/14
Filing Date
2020-02-03
Application No.
17427988
Claims
3
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.